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Abstract
Background: Glioblastoma multiforme (GBM) is among the most lethal of all human tumors, with frequent local
recurrences after radiation therapy (RT). The mechanism accounting for such a recurrence pattern is unclear. It has
classically been attributed to local recurrence of treatment-resistant cells. However, accumulating evidence suggests
that additional mechanisms exist that involve the migration of tumor or tumor stem cells from other brain regions
to tumor bed. VEGFs are well-known mitogens and can be up-regulated after RT. Here, we examine the effect of
irradiation-induced VEGF on glioma cell motility.
Materials and methods: U251 and LN18 cell lines were used to generate irradiated-conditioned medium (IR-CM).
At 72 h after irradiation, the supernatants were harvested. VEGF level in IR-CM was quantified by ELISA, and
expression levels for VEGF mRNA were detected by RT-PCR. In vitro cancer cell motility was measured in chambers
coated with/without Matrigel and IR-CM as a cell motility enhancer and a VEGF antibody as a neutralizer of VEGF
bioactivity. Immunoblots were performed to evaluate the activity of cell motility-related kinases. Proliferation of
GBM cells after treatment was measured by flow cytometry.
Results: Irradiation increased the level of VEGF mRNA that was mitigated by pre-RT exposure to Actinomycin D.
U251 glioma cell motility (migration and invasion) was enhanced by adding IR-CM to un-irradiated cells (174.9 ±
11.4% and 334.2 ± 46% of control, respectively). When we added VEGF antibody to IR-CM, this enhanced cell
motility was negated (110.3 ± 12.0% and 105.7 ± 14.0% of control, respectively). Immunoblot analysis revealed that
IR-CM increased phosphorylation of VEGF receptor-2 (VEGFR2) secondary to an increase in VEGF, with a
concomitant increase of phosphorylation of the downstream targets (Src and FAK). Increased phosphorylation was
mitigated by adding VEGF antibody to IR-CM. There was no difference in the mitotic index of GBM cells treated
with and without IR-CM and VEGF.
Conclusions: These results indicate that cell motility can be enhanced by conditioned medium from irradiated
cells in vitro through stimulation of VEGFR2 signaling pathways and suggest that this effect involves the secretion
of radiation-induced VEGF, leading to an increase in glioma cell motility.
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Background
Glioblastoma multiforme (GBM) is the most common
and lethal primary malignant brain tumor in adults, well
known for its diffusely infiltrative pattern several centi-
meters away from the primary disease site. Surgical
removal followed by radiation therapy (RT) with che-
motherapy represents standard treatment [1]. Due to
the potential morbidity of whole-brain irradiation to 60
Gy, the planning target volume for RT consists of the
tumor volume, defined by magnetic resonance (MR)
imaging, with a 2 ~ 3 cm margin of surrounding tissue
considered to be at risk for microscopic tumor invasion.
However, more than 80% of untreated patients have
microscopic disease within several centimeters of the
contrast-enhancing tumor margin defined by computed
tomography (CT) scan, and 47% of cases demonstrate
histological evidence of tumor spread to the contralat-
eral hemisphere [2,3]. This diffuse growth pattern of
GBM may account for the unfavorable outcome of local
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to the morbidities of both the disease and the treatment.
Because the majority of tumor recurrences are found
immediately adjacent to the site of resection or nearby
surgical resection cavity [3,4], it has been hypothesized
that radioresistance of residual tumor cells after surgical
resection accounts for the local recurrence pattern. The
results of recent studies, however, have demonstrated
that it may also be due to changes in cellular microen-
vironments in the brain after treatment [5-8]. In addi-
tion, accumulating evidence suggests that molecules that
are induced by primary tumors directly regulate motility
in various types of malignant cells [9-14].
Vascular endothelial growth factor (VEGF), is a family
of structurally related proteins, including VEGF-A,
VEGF-B, VEGF-C, VEGF-D, and is essential for regulat-
ing the key steps of cell proliferation and migration.
VEGF expression is up-regulated by various types of
pathological conditions, malignant tumors and stresses,
including surgery and RT [5-9,15]. VEGF secreted from
primary tumors promotes cancer progression by indu-
cing angiogenesis via VEGF receptors (VEGFRs) on
endothelial cells but also signals directly through its
receptors expressed on both cells of hematopoietic ori-
gin and a variety of tumor cells [9,12,13,16]. When
VEGF binds to VEGFR, the biological effect is to cause
ligand-induced dimerization and oligomerization, which
activate the receptor’s intrinsic tyrosine kinase activity,
resulting in auto- and trans-phosphorylation on tyrosine
residues in the cytoplasmic domain [17]. Enhanced
VEGF expression and VEGFR activation induce malig-
nant cell motility [10,13]. Indeed, VEGF can activate
several tyrosine kinases, including Src kinase (Src), focal
adhesion kinase (FAK), and paxillin [11,18-20]. Because
t h e s es i g n a l i n gk i n a s e sp l a yar o l ei nm o d u l a t i n gc e l l
motility [10,21-23], we evaluated the effects of IR in
creating a conditioned medium that could increase
tumor cell motility.
The data presented indicate that radiation-induced
VEGF in cultured medium collected from irradiated
glioma cells enhanced tumor motility through VEGF-sti-
mulated Src and FAK phosphorylation. We also show
that blocking the action of radiation-induced VEGF
using neutralizing, anti-VEGF antibodies resulted in
decreased tumor cell invasion and migration.
Materials and methods
Materials
VEGF165 and anti-human VEGF antibody were pur-
chased from R & D Systems, Inc. (Minneapolis, NM).
The anti-FAK antibodies used for Western blotting as
well as the anti-paxillin were mouse monoclonal antibo-
dies purchased from BD Biosciences (San Jose, CA). The
phosphospecific rabbit antibodies against FAK at Y861
and Y925 were from Millipore (Temecula, CA) and Cell
Signaling Technology (Danvers, MA), respectively, and
VEGFR2 at Y996 and Y1059 from Cell Signaling Tech-
nology. Horseradish-peroxidase-conjugated secondary
antibodies against mouse and rabbit immunoglobulins
were from Santa Cruz Biotechnology (Santa Cruz, CA).
Actinomycin D (Act D) was obtained from Sigma Che-
mical Co. (St. Louis, MO).
Cell lines and tumor-conditioned medium
The U251 and LN18 human GBM cell lines were
obtained from the Tumor Repository at the National
Cancer Institute at Frederick (Frederick, MD). Cells
were grown in Dulbecco’s modified eagle medium
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with
glutamate (5 mmol/L) and 5% fetal bovine serum (FBS),
and maintained at 37 C, 5% CO2.T og e n e r a t ec o n d i -
tioned medium (CM), glioma cells were seeded at a den-
s i t yo f5×1 0
5 cells in 100 mm dishes. At 60%
confluence, the cells were removed from the culture
medium, washed three times with phosphate-buffered
saline (PBS) and supplemented with 7 mL of serum-free
medium. Glioma cells were then irradiated at a dose of
0 . 5t o1 0G ya tr o o mt e m p e r a t u r eu s i n gaP a n t a k
(Solon, OH) X-ray source at a dose rate of 2.28 Gy/min.
After cultivation for 72 h, the supernatant of gliomas
was harvested, filtered to remove debris and stored at
−20 C.
VEGF protein quantification
To quantify the VEGF protein that was released into the
tumor-conditioned media of U251 and LN18 cells, the
media were analyzed by a specific enzyme-linked immu-
nosorbent assay (ELISA) kit from R&D Systems, Inc.,
according to the manufacturer’s recommendation.
RT-PCR and relative quantification of VEGF mRNA
transcripts
After removing the supernatant from culture dishes, the
total RNA of the cells was isolated using TRIzol, accord-
ing to the protocol supplied by the manufacturer (Invi-
trogen, Carlsbad, CA); the concentration of RNA was
determined spectrophotometrically at 260 nm. RNA was
further purified using RNeasy Mini Kit according to the
manufacturer’s recommendations (Qiagen, Valencia,
CA), with the addition of DNase digestion using RNase-
free DNase (Qiagen), and stored at -20 C until use.
Complementary first-strand DNA was generated from
RNA, which was isolated from glioma cells irradiated
with and without pretreatment for 1 h with Act D (5
μg/ml), using the TaqMan RT-PCR kits (Perkin-Elmer
Applied Biosystems, Foster City, CA), according to the
manufacturer’s protocol. The PCR conditions involved
an initial denaturation step at 94 C for 5 min, followed
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30 s. Primers and probes for VEGF and Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA tran-
scripts were purchased from Perkin-Elmer Applied Bio-
systems. PCR was performed using TaqMan RT-PCR
kits (Perkin-Elmer Applied Biosystems), according to the
manufacturer’s protocol.
In vitro motility assay
Invasion was measured using 24-well BioCoat Matrigel
invasion chambers (Becton Dickinson Labware, Bedford,
MA) with an 8 μm pore polyethylene teraphthalate
(PET) membrane coated with Matrigel. The lower com-
partment contained 0.75 ml of conditioned medium or
human VEGF165 (R&D Systems) as a chemoattractant,
or serum-free DMEM medium as a control. In the
upper compartment, 5 × 10
4 cells/well were placed in
triplicate wells. For migration assays, 5 × 10
4 cells/well
were placed in the top chamber of non-coated PET
membranes (24-well insert, pore size 8-μm; Becton
Dickinson Labware). The cells were incubated for 22 h
and those that did not migrate through the pores in the
membrane were removed by scraping the membrane
with a cotton swab. Cells transversing the membrane
were fixed and stained with Diff-Quick (Dade, Unters-
chleissheim, Germany). Stained cells were counted by
light microscopy in nine randomly chosen high-power
fields (x 200). Images were captured by a Photometrics
Sensys CCD camera (Roper Scientific, Tucson, AZ) and
imported into an IP Labs image analysis software pack-
age (Scanalytics, Inc., Fairfax, VA). Experiments were
performed in triplicate.
Neutralization of VEGF bioactivity
To analyze the VEGF effect of VEGF-neutralized condi-
tioned medium on glioma cell motility, monoclonal
anti-human VEGF165 was added to the conditioned
m e d i u ma n du s e df o rt h ein vitro motility assay (see
above).
Immunoblotting
Equal quantities of protein were separated by sodium
dodecyle sulfate/polyacrylamide gel electrophoresis
(SDS/PAGE) and transferred to polyvinyldene fluoride
(PVDF) membrane (Millipore). The membranes were
blocked with Tris-buffered saline/Tween (0.15) plus 5%
dried nonfat milk for 1 h at room temperature and
incubated with the desired primary antibody diluted
1:1000 in blocking buffer overnight at 4 C. Membranes
were probed with antibodies to phospho-VEGFR2
Y996,
phospho-VEGFR2
Y1059,p h o s p h o - S r c
Y461, phospho-
FAK
Y861, phospho-FAK
Y925, Src and FAK. Primary anti-
body incubation was followed by incubation with a
horseradish peroxidase-conjugated secondary antibody
( g o a ta n t i - m o u s eo rg o a ta n t i - r a b b i t )d i l u t e d1 : 2 0 0 0i n
blocking buffer for 2 h at room temperature. Proteins
were visualized with electrochemiluminescence detection
reagents (Santa Cruz Biotechnology) and detected by
autoradiography.
Proliferation assay
Evaluation of cell cycle phase distribution was per-
formed using flow cytometry. U251 GBM glioma cells
were incubated for 22 h with conditioned medium or
VEGF165 (25 ng/mL)-containing medium. Samples were
fixed, stained with propidium iodide and analyzed using
flow cytometry (Guava Technologies, Hayward, CA).
Mitotic cells were distinguished from G2 cells, and the
mitotic index was determined according to the expres-
sion of phosphorylated histone H3 (Upstate Biotechnol-
ogy, Charlottesville, VA) detected in the 4 N DNA
content population by the flow cytometric method of
Xu et al. [24].
Statistical analysis
In vitro experiments were repeated three times, and sta-
tistical analysis was performed using a student’s t-test.
Data are presented as mean ± standard deviation (SD).
A p value < 0.05 was considered significant.
Results
VEGF protein quantification
To measure the effects of IR on VEGF production in GBM
tumor cells, subconfluent U251 and LN18 cells were
exposed to graded doses of irradiation (IR). Three days
after IR, the supernatants of each cell line were collected
to generate irradiated-conditioned medium (IR-CM).
VEGF levels were then measured by ELISA. The mean
VEGF level in the media from unirradiated glioma cell
lines was low (0.034 ± 0.003 pg/1000 cells in U251 and
0.032 ± 0.001 pg/1000 cells in LN18). In each cell line,
however, a significant increase in VEGF levels after IR was
measured (Figure 1). There was an IR dose-dependent
increase of VEGF up to 2 Gy. At higher radiation doses,
up to 10 Gy, VEGF levels in IR-CM were lower than those
at 2 Gy but still remained higher than those in unirra-
diated supernatants. The U251 cell lines showed signifi-
cantly higher VEGF secretion than LN18 cell lines treated
with 2 Gy IR (98.504 ± 0.098 pg/1000 cells and 74.096 ±
0.029 pg/1000 cells, respectively; p = 0.003).
RT-PCR and relative quantification of VEGF mRNA
transcripts
To determine whether the IR-induced VEGF increase was
at the transcriptional level, VEGF transcriptions were
assessed in U251 and LN18 cells by RT-PCR. VEGF tran-
scripts were induced 55-fold in U251 and 28-fold in LN18
at 72 h after IR (Figure 2). Radiation-induced VEGF
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μg/mL) treatment 1 h prior to IR. These findings show
that IR induces VEGF expression in glioma cells due to an
increase in VEGF transcription. Based on this data and the
clinical relevance of the radiation dose, 2 Gy of IR was
used for subsequent experiments.
In vitro motility assays
To determine the effects of IR-induced VEGF on GBM
tumor cell motility, we performed invasion assays on
Matrigel-coated membranes and migration assays on
uncoated membranes. Because VEGF expression after IR
was higher in U251 than in LN18, we used the U251
glioma cell line for motility assays. IR-CM was used as a
chemoattractant for the invasion and migration assays
(Figure 3). The invasion rate of U251 glioma cells was
increased with IR-CM (334.2 ± 46% of control; p =
0.002). IR-CM also enhanced U251 glioma cell migra-
tion rates (174.9 ± 11.4% of control; p = 0.001). Invasion
and migration rates were also increased when we used
the recombinant VEGF165 (5 ng/mL) as a positive con-
trol (296 ± 8.24% and 213.98 ± 49.7% of control, respec-
tively). There were no statistically significant differences
in invasion or migration rates between IR-CM and
VEGF165 groups (p = 0.119). These data suggest that IR-
induced VEGF in IR-CM is sufficient to cause the
increased invasion and migration seen in the recombi-
nant VEGF.
To assess the importance of the effect of VEGF in the
tumor-conditioned medium, VEGF neutralizing antibody
was added, and the motility assay was repeated. Various
concentrations of anti-VEGF antibody (anti-human
VEGF165;1 ,1 0a n d2 0μg/mL) were added to IR-CM,
and the invasion and migration assays were performed
as described above. Compared to IR-CM, there was a
significant reduction of U251 glioma cell motility when
anti-VEGF antibody was added to IR-CM (Figure 3B).
Invasion rates were significantly decreased by adding
anti-VEGF antibody to IR-CM, and their diminutions
were correlated with concentration of antibody (135.9 ±
4.8% of control with 10 μg/mL of anti-VEGF antibody,
and 105.7 ± 14% of control with 20 μg/mL of anti-
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Figure 1 The concentration of VEGF protein in conditioned medium. Cells in serum-containing (5%) medium were washed with PBS and
cultured in fresh serum-free medium. Culture supernatants were harvested from irradiated (0.5 ~ 10 Gy) or nonirradiated glioma cells after 72 h
of incubation and VEGF protein measured by ELISA. Each value represents the mean of three independent experiments; bars, ± SD.
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Figure 2 VEGF transcription in glioma cells.U 2 5 1a n dL N 1 8
glioma cells in culture dishes with serum-free medium were
pretreated with or without actinomycin. Total RNA was isolated at
72 h after irradiation (IR) and subjected to RT-PCR analysis. The data
represent the mean of three independent experiments; bars, ± SD.
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Page 4 of 9VEGF antibody). Enhanced migration rates observed
with IR-CM were nullified with 10 μg/mL of antibody
(109.9 ± 15.5% of control, p = 0.348), and increasing
VEGF antibody up to 20 μg/mL did not further decrease
the migration rates (118.2 ± 21.6% of control, p =
0.612). These data indicate that VEGF is necessary for
causing the increased invasion and motility seen from
tumor-conditioned medium and can be inhibited by a
neutralizing antibody.
Proliferation assay
To determine whether the enhanced GBM cellular moti-
lity was due to an increased number of cells secondary
to the mitogenic effects of VEGF, we measured the
mitotic index after the addition of IR-CM or VEGF sti-
mulation of proliferation of GBM tumor cells using the
method of Xu et al. [24]. This assay determines the per-
centage of mitotic cells in the 4 N population according
to the flow cytometric analysis of phosphorylated his-
tone H3, which is specifically expressed in mitotic cells.
After 22 h of exposure to IR-CM or VEGF (25 ng/ml),
there was no change in the mitotic index of U251 cells
i nt h ec o n t r o l ,I R - C Ma n dV E G Fg r o u p s( F i g u r e4 ) .
These data indicate that VEGF in conditioned medium
significantly enhances the migration and invasion
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Figure 3 Glioma cell motility. U251 glioma cells were irradiated (2 Gy) and incubated in serum-free medium for 72 h, irradiated conditioned
medium (IR-CM) then was collected from the supernatant of culture dishes and used for cell motility assays. Cell motility was evaluated using
24-well chambers with an 8-μm pore polyethylene teraphthalate (PET) membrane coated with matrigel for invasion assays, and non-coated PET
membranes for migration assays. The lower compartment contained 0.75 ml of serum-free medium (control), IR-CM and serum-free medium
with VEGF (5 ng/ml) (A). To neutralize VEGF activity in IR-CM, IR-CM was supplemented with monoclonal anti-human VEGF antibody (1, 10 and
20 μg/ml) (B). 5 × 10
4 cells were placed in top chamber, incubated for 22 h and glioma cells transversing the membrane were fixed and
stained. Stained cells were counted by light microscopy in nine randomly chosen high-power fields (x 200). Images were captured by a
Photometrics Sensys CCD camera and imported into IP Labs image analysis software package. Columns, mean from three independent
experiments; bars, ± SD.
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Figure 4 Influence of irradiated conditioned medium (IR-CM)
and VEGF on the proliferation of U251 glioma cell. U251 GBM
glioma cells were incubated for 22 h with conditioned medium or
VEGF165 (25 ng/mL) contained medium. Evaluation of cells in
mitotic phase was performed using flow cytometry. Samples were
fixed, stained with propidium iodide, and analyzed using flow
cytometry. Mitotic cells were distinguished from G2 cells, and the
mitotic index was determined according to the expression of
phosphorylated histone H3 as detected in the 4 N DNA content
population by the flow cytometric method of Xu et al. [23]. The
data represent the mean of three independent experiments; bars,±
SD.
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an increase in proliferation.
Immunoblotting
In tumor cells, motility is regulated partly by the activa-
tion of Src and FAK. A variety of factors are known to
induce Src and FAK activation. VEGF is one of the
molecules that can stimulate the phosphorylation of
FAK through Src family activation [19,20]. To determine
whether Src and/or FAK can be activated when glioma
cells are treated with conditioned medium, first we
investigated the activation status of VEGF receptor 2
(VEGFR2) after treatment with IR-CM. As shown in
Figure 5A, treatment of U251 glioma cells with IR-CM
enhanced phosphorylated VEGFR2 at both Y996 and
Y1059 (210% of control and 187% of control, respec-
tively). Increased phosphorylation of VEGFR2 was miti-
gated by adding VEGF antibody (10 μg/ml) in IR-CM.
To determine the effects of VEGF in IR-CM on down-
stream signaling of VEGFR2, we investigated the status
of Src and FAK phosphorylation with IR-CM treatment.
In Figure 5B, treatment of U251 glioma cells with IR-
CM enhanced phosphorylation of Src kinase at Y461.
Moreover, after 16 h of incubation of GBM glioma cells
with IR-CM, U251 cells also expressed increased
phosphorylation of FAK at both Y861 and Y925. To
determine whether the enhancement of phosphorylation
of Src and FAK in response to IR-CM was due to the
effects of VEGF in IR-CM, anti-VEGF antibody was
added to IR-CM. Anti-VEGF antibody in IR-CM effec-
tively blocked Src and FAK phosphorylation.
Taken together, our data show VEGF in IR-CM can
phosphorylate VEGFR2, leading to a VEGFR2-mediated
downstream signaling (Src and FAK) cascade, thereby
mediating enhanced cellular invasion and migration in
GBM tumor cells.
Discussion
Cytokines are released in response to a diverse range of
cellular stresses such as infection, inflammation and
injury, and regulate a variety of cellular functions. It has
been reported that alteration of cytokines can change
cellular interactions [8,9,12,13,25-28]. VEGF is an
important angiogenic factor and induces a potent mito-
genic signal for endothelial cells by binding VEGFRs on
endothelial cells. Expression of VEGFRs, however, has
also been identified in other cell types, including glio-
blastoma cell lines [29]. These data suggest that, in addi-
tion to angiogenic function, VEGF may affect the
function of cancer cells that express VEGFRs [10,12,13].
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Figure 5 The effects of irradiated conditioned medium (IR-CM) on activation of kinases in glioma cells. After 16 h incubation of GBM
glioma cells with IR-CM ± monoclonal anti-human VEGF165 antibody (R&D System), cells were harvested, processed to make lysates and the
supernatant was collected. Equal quantities of protein were separated by SDS/PAGE and transferred to PVDF membrane. The membranes were
blocked with 5% dried non-fat milk for 1 h at room temperature and incubated with the desired primary antibody diluted 1:1000 in blocking
buffer overnight at 4 C. Membranes were probed with antibodies to phospho VEGFR2
Y996, phospho VEGFR2
Y1056, Src
Y461, phospho FAK
Y861 and
phospho FAK
Y925. Primary antibody incubation was followed by incubation with a horseradish peroxidase-conjugated secondary antibody in
blocking buffer for 2 h at room temperature. Proteins were visualized with electrochemiluminescence detection reagents and detected by
autoradiography. (A) IR-CM effect on phosphorylation of VEGFR2 in U251 glioma cells. (B) IR-CM with/without VEGF antibody (10 μg/ml) effect
on the phosphorylation of Src and FAK in U251 glioma cells. Blots are representative images of three replicates.
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extracellular VEGF (tumor-derived) concentration in
two GBM cell lines (U251 and LN18) in response to a
range of radiation doses (0.5-10 Gy). VEGF concentra-
tion in each cell line after radiation increased and
showed a peak level at conventional daily radiation
doses (1 ~ 3 Gy) (Figure 1). With higher doses, however,
we found that VEGF concentration did not further
increase. Our results are similar to another study, which
showed increased VEGF levels in conditioned medium
24 h after radiation (0 vs.5 ,1 0a n d2 0G y )b u tt h e
increase did not occur in a radiation dose-dependent
manner [8]. Moreover, increased VEGF levels in IR-CM
resulted from radiation-induced increased VEGF tran-
scription in glioma cells (Figure 2). These results suggest
that glioma cells produce and secrete VEGF after a con-
ventional dose of radiation.
VEGF has been reported to regulate the functions of
endothelial cells by binding VEGFRs on the cells. In
addition to their expression on endothelial cells,
VEGFRs have also been identified on hematopoietic ori-
gin cells and human cancer cells [9,12,13,16]. Damiano
et al. [30] report the expression of VEGFRs on glioma
cells and their signaling activity in conjunction with the
epidermal growth factor receptor. Induction of cell
motility in response to mitogenic factors such as VEGF
is a tightly regulated process, requiring the coordination
of a complex set of signals involving the extracellular
matrix, integrins and the actin cytoskeletal-associated
motile apparatus. Specifically, VEGFR2 activation results
in the activation of Src and FAK.
In this study, we evaluated the effect of IR-CM or
VEGF on the motility of glioma cells. As stated above,
VEGF showed its enhanced migratory effects on glioma
cells; both the invasion and migration index were
increased in our study. Interestingly, we noticed that the
glioma cell motility assay with IR-CM also resulted in
an increase of the invasion and migration index; VEGF
antibody, however, attenuated the migration activity in
IR-CM (Figure 3). These data suggest that increased
VEGF in IR-CM is necessary for increasing invasion and
motility. These results are consistent with other data
that have demonstrated the enhanced migratory effects
of VEGF on various types of human cancer cells
[9-13,16].
To investigate the mechanism responsible for mediat-
ing the VEGF in IR-CM-induced glioma cell motility,
we surveyed VEGFR2-mediated downstream signaling
pathways. VEGF has been reported to be capable of acti-
vating additional kinases, which play an important role
in cell motility [11,18,19,21]. First, the Src are non-
receptor tyrosine kinases, ubiquitously expressed in cells
a n di n v o l v e di nt h ec e l l u l a rmotility pathway. VEGF-
induced Src activation and signaling also has been
reported and is associated with poor prognosis in cancer
patients [10,11,20,31]. Second, FAK is a widely
expressed cytoplasmic protein tyrosine kinase that is
phosphorylated in response to various stresses, and it
plays an important role in controlling several fundamen-
tal cellular biological functions, including cell motility
[32]. Glioma cells with low levels of phosphorylated
FAK show motility arrest [33]. Interestingly, VEGF sti-
mulates the tyrosine phosphorylation of FAK [19,20].
The phosphorylated FAK is associated with increased
formation of stress fibers, recruitment of FAK to new
focal adhesions and increased cell motility. It is also well
known that FAK activation is closely related to Src
activity [34]. Although the mechanism underlying
VEGF-stimulated Src and FAK phosphorylation is still
under the evaluation, data support the concept that cell
motility is regulated by VEGF-mediated VEGFR2 activa-
tion and interaction with its downstream protein
kinases, including Src and FAK [20].
Lesslie et al. [10] and Munshi et al. [11] reported
VEGF-activated Src in human cancer cells. These results
were consistent with data in this study. Glioma cells
treated with VEGF showed enhanced Src activity. We
also noticed that glioma cells treated with IR-CM
showed increased Src and FAK expression. Enhanced
kinase activities in glioma cells, however, were attenu-
ated by adding VEGF antibody to IR-CM. These results
suggest that radiation-induced VEGF in glioma cells
might account for activation of Src and FAK, thereby
enhancing cellular motility.
The data presented here indicate that glioma tumor
cells produce VEGF after a conventional dose of radia-
tion and, moreover, show that radiation-induced VEGF
affects tumor cell motility by activating Src and FAK
kinase. The studies described here addressed only the
effect of radiation-induced VEGF on glioma cells in
vitro. These findings support a model in which tumor-
derived VEGF induced by radiation is both necessary
and sufficient to increase tumor cell motility. Microsco-
pically scattered glioma cells around a gross tumor area
could be affected by radiation-induced VEGF during
and after treatment. This may provide an additional
mechanistic rationale to explain the frequent tumor
recurrences seen with GBM after radiation therapy. It
also suggests the potential to improve outcomes by
combining radiation therapy with anti-VEGF agents.
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